AG Scheich

Research focus

Our group focuses on translational cancer research to ultimately improve patient outcomes. Our work is based on two main pillars:

 

1. Lymphoid Malignancies

Lymphomas are a heterogenous group of diseases with a variety of different entities and subtypes. Among aggressive lymphomas, diffuse large B cell lymphoma (DLBCL) is the most common subtype. Although a substantial number of patients can be cured with standard-of-care therapies, many patients experience disease relapse. We combine state-of-the art “proteogenomics” (genome-wide CRISPR screens and functional proteomics), super resolution microscopy (dSTORM, SIM) to understand the complex biology and oncogenic signaling in these cancers to improve current therapeutic approaches.

 

1. Microbiome in Oncology

Together with Dr. Björn Steffen, we are focusing on microbiome alterations in patients with cancer. We apply modern microbiome sequencing technologies (16S-sequencing, shotgun sequencing) together with FACS and single cell based immune profiling approaches to dissect the crosstalk between the microbiome and the immune system in patients with cancer.

Team

Dr. Sebastian Scheich (Lad Head)

Dr. Björn Steffen (Co-lead Microbiome in Oncology)

Sylvia Pfundt (Technician)

Sabrina Becker (PhD student)

Rebecca Poss (PhD student)

Sophie Lund (PhD student)

Nico Zeltner (Clinical Fellow)

Ana Jankovic (MD student)

Research funding

Deutsche Krebshilfe

Bundesministerium für Bildung und Forschung (BMBF, INITIALISE-Programm)

Frankfurt Cancer Institute

Selected publications

Scheich S., Chen J., Liu J. et al. (2023): Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer Disc. 2023 May 4;CD-22-1401.doi: 10.1158/2159-8290.CD-22-1401.Online ahead of print.

Wilke A.C., Doebele C….Scheich S….Oellerich T. (2022): SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood 139, 538-553, doi:10.1182/blood.2021012081.

Fish K., Comoglio F….Scheich S…Oellerich T. (2020): Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26318-26327. doi: 10.1073/pnas.2007946117. Epub 2020 Oct 5.

Weber S., Hogardt M…Scheich S. (2019): Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. Ann Hematol. 98(3):763-773

Scheich S., …Steffen B. (2017): Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Cancer, 2018 Jan 15;124(2):286-296.